CD267 polyclonal, anti-human

Protein Family: Receptors and Channels, Cellular Antigens

Pathway and Disease: Signaling Molecules and Interaction, Immune System

Description:
Tumor necrosis factor receptor superfamily member 13B (CD267) is a receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. CD267 mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. CD267 is involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. Defects in CD267 are the cause of immunodeficiency common variable type 2 (CVID2). CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins. The numbers of circulating B cells is usually in the normal range, but can be low.

Alternate Names: Tumor necrosis factor receptor superfamily member 13B, Transmembrane activator and CAML interactor, CD267, TNFRSF13B, TACI

Application Notes: E: 1:10,000-1:50,000; WB: 1:500-1:1,000

Accession No.: O14836

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human CD267.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4 with 0.09% sodium azide. Antibody was purified by Protein-G affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.